The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

The Health Care Select Sector SPDR ETF (XLV) has underperformed the broad market significantly in 2025, down 3% year-to-date despite the S&P 500's continued rally. This divergence reflects structural headwinds in the healthcare sector, though the fund's 14% one-year return suggests resilience on a longer timeframe. The article's premise centers on identifying catalysts that could narrow this performance gap in 2026.

The underperformance of XLV relative to the S&P 500 highlights a sectoral rotation dynamic where large-cap tech and growth equities have dominated recent gains. Healthcare holdings like JNJ and ABBV face valuation pressures and policy uncertainty that have constrained investor appetite. The fund's composition—including pharmaceuticals, medical devices, and healthcare services—remains sensitive to regulatory and reimbursement risks that broader indices do not share equally.

The article's reference to a meaningfully different policy setup for 2026 suggests potential tailwinds from regulatory clarity or policy shifts. Changes in drug pricing frameworks, FDA approval timelines, or Medicare reimbursement policies could materially improve near-term sentiment. Conversely, continued inflationary pressures on healthcare costs or stricter margin compression could extend underperformance.

Sector implication: Healthcare's 2026 relative performance hinges on macro policy clarity and sector-specific catalysts rather than broad market momentum. A mean-reversion trade in XLV depends on exogenous policy events rather than fundamental valuation improvement, making timing and conviction critical for sector rotation strategies.